Xarah Fe Kit
Product Images NDC 70700-310

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Xarah Fe (NDC 70700-310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 01)

Structural Formula (Image 01)
This text indicates the possible presence of a combination medication containing Norethindrone Acetate and Ethinyl Estradiol. Norethindrone Acetate is a progestin hormone, while Ethinyl Estradiol is an estrogen hormone. This combination is commonly used in oral contraceptives to prevent pregnancy by inhibiting ovulation and altering the cervical mucus and endometrium to make it harder for sperm to reach the uterus or for a fertilized egg to implant.*
FDA Label Image

Concentrations (Image 02)

FDA Label Image

Figure 2. Mean Percent Reduction In Total Lesion Counts From Baseline To Each 28-day Cycle And Mean Total Lesion Counts At Each Cycle Following Administration Of Norethindrone Acetate And Ethinyl Estradiol Tablets And Ferrous Fumarate Tablets And Placebo (statistically Significant Differences Were Not Found In Both Studies Individually Until Cycle 6) (Image 03)

Figure 2. Mean Percent Reduction In Total Lesion Counts From Baseline To Each 28-day Cycle And Mean Total Lesion Counts At Each Cycle Following Administration Of Norethindrone Acetate And Ethinyl Estradiol Tablets And Ferrous Fumarate Tablets And Placebo (statistically Significant Differences Were Not Found In Both Studies Individually Until Cycle 6) (Image 03)
This text appears to be a comparison of lesion counts between a group taking Norethindrone Acetate and Ethinyl Estradiol Tablets with Ferrous Fumarate Tablets and a placebo group. The study shows a mean percent reduction in lesion counts for both groups.*
FDA Label Image

Figure 3. Circulatory Disease Mortality Rates Per 100,000 Woman Years By Age, Smoking Status And Oral Contraceptive Use (Image 04)

FDA Label Image

Blister (Image 05)

Blister (Image 05)
This text provides instructions for starting birth control pills based on the day of the week your period begins. It mentions using a day label sticker and shows a sequence of days (MON, TUE, WED, THU, FRI, SAT, SUN) for reference. Additionally, it instructs to start taking the pills from left to right.*
FDA Label Image

Blister (Image 06)

Blister (Image 06)
This text is a set of instructions for starting birth control pills based on when your period begins. It mentions that if your period starts on a day other than Sunday, you should place the day label sticker with the first day of your period. It also provides a layout of the days of the week for pill intake, instructing to take pills from left to right. It is important to follow these directions to ensure the correct and effective use of the birth control pills.*
FDA Label Image

3s Carton (Image 07)

FDA Label Image

Figure 4. Risk Of Breast Cancer With Combined Oral Contraceptive Use (Image 08)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.